Proteomic Approach Reveals FKBP4 and S100A9 as Potential Prediction Markers of Therapeutic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer

详细信息    查看全文

• 作者：Won Suk Yang ; Hyeong-Gon Moon ; Hee Sung Kim ; Eui-Ju Choi ; Myeong-Hee Yu ; Dong-Young Noh ; Cheolju Lee
• 刊名：Journal of Proteome Research
• 出版年：2012
• 出版时间：February 3, 2012
• 年：2012
• 卷：11
• 期：2
• 页码：1078-1088
• 全文大小：1151K
• 年卷期：v.11,no.2(February 3, 2012)
• ISSN：1535-3907

文摘

Although doxorubicin (Doxo) and docetaxel (Docet) in combination are widely used in treatment regimens for a broad spectrum of breast cancer patients, a major obstacle has emerged in that some patients are intrinsically resistant to these chemotherapeutics. Our study aimed to discover potential prediction markers of drug resistance in needle-biopsied tissues of breast cancer patients prior to neoadjuvant chemotherapy. Tissues collected before chemotherapy were analyzed by mass spectrometry. A total of 2,331 proteins were identified and comparatively quantified between drug sensitive (DS) and drug resistant (DR) patient groups by spectral count. Of them, 298 proteins were differentially expressed by more than 1.5-fold. Some of the differentially expressed proteins (DEPs) were further confirmed by Western blotting. Bioinformatic analysis revealed that the DEPs were largely associated with drug metabolism, acute phase response signaling, and fatty acid elongation in mitochondria. Clinical validation of two selected proteins by immunohistochemistry found that FKBP4 and S100A9 might be putative prediction markers in discriminating the DR group from the DS group of breast cancer patients. The results demonstrate that a quantitative proteomics/bioinformatics approach is useful for discovering prediction markers of drug resistance, and possibly for the development of a new therapeutic strategy.

Keywords:

neoadjuvant chemotherapy; drug resistance; quantitative proteomics; FKBP4; S100A9